A Phase 3b Study of Vernakalant Injection in Patients With Recent Onset Symptomatic Atrial Fibrillation (AF)(MK-6621-045)
Status:
Terminated
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of vernakalant injection in
subjects with recent onset (AF > 3 hours to <= 7 days), symptomatic atrial fibrillation and
no evidence or history of congestive heart failure.